Intellia To Test CRISPR-Engineered TCR-T Cell Candidate In Acute Myeloid Leukemia Patients
The FDA has signed off Intellia Therapeutics Inc’s (NASDAQ:NTLA) investigational new drug (IND) application for NTLA-5001. Related Content: Intellia Shares Shoot Higher…